Clinical trial NCT02716272: Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Official title: A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Mesothelioma
Keywords: mesothelioma
immunotherapy
nivolumab
ipilimumab
Lead sponsor: Intergroupe Francophone de Cancerologie Thoracique
Sponsor class: OTHER
First posted: 2016-03-23
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The sponsor raise the hypothesis that inhibition of immune PD-1+/- CTLA-4 check-point(s) would delay tumor progression in patients with unresectable MPM, experiencing disease progression after one or two lines of chemotherapy including at least first-line with pemetrexed and platinum, without altering significantly the quality of life of patients.


Eligibility criteria: Inclusion Criteria:

1. Histologically proved diagnosis of unresectable malignant pleural Mesothelioma (MPM)
2. Available (archival and/or fresh) pathological samples for centralized PD-L1 expression assessment by immunohistochemistry
3. Age ≥ 18 years old; male and female
4. ECOG Performance status 0-1
5. Weight loss \< 10% during last 3 months
6. Life expectancy \> 12 weeks
7. Documented progression of the MPM, assessed by computed tomography (CT) -Scan.
8. Measurable disease, defined as at least 1 lesion (measurable) that can be accurately assessed at baseline by CT-Scan and is suitable for repeated assessment using modified Response Evaluation Criteria in Solid Tumors \[RECIST\] for pleural mesothelioma (Byrne 2004; Therasse 2006).
9. Previous treatment by 1 or 2 systemic chemotherapy lines (1 line of chemotherapy considered if the patient received ≥2 cycles of this chemotherapy), including at least one line with pemetrexed in combination with platinum agent (i.e. "gold standard chemotherapy in MPM; triplet including bevacizumab also accepted)
10. Written informed consent
11. Patients must have adequate organ function : creatinine clearance \> 50 mL/min (Cockcroft formula), Neutrophiles count \> 1500/mm3; Platelets \> 100 000/mm3 ; Hemoglobin \> 9 g/dL; hepatic enzymes \< 3N with total bilirubin ≤ 1.5 × ULN (upper limit of normal) except subjects with documented Gilbert's syndrome (≤ 5 × ULN) or liver metastasis, who must have a baseline total bilirubin ≤ 3.0 mg/dL
12. Recovered from all toxicities associated with prior treatment, to acceptable baseline status, or a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia or vitiligo
13. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. They must also refrain from egg cell donation for 6 months after the final dose of investigational product. Men receiving nivolumab and who are sexually active with women of childbearing potential will be instructed to adhere to contraception for a period of 31 weeks after the last dose of nivolumab.

Exclusion Criteria:

1. Patients with primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma
2. Patients with a recent history of other malignancies except adequately treated non-melanoma skin cancer, and curatively treated in-situ cancer. Patients with prostate adenocarcinoma diagnosed less than 5 years could be included in case of localized prostate cancer with good outcome according the Amico classification: ≤ T2a and Gleason Score ≤6 and PSA blood level ≤10 ng/ml, and treated with curative intent (surgery or radiotherapy) without chemotherapy. Patients with history of solid tumors, including adenocarcinoma, treated with curative intent and without any evidence of disease \>5 years can be included as well.
3. Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy with no evolution within the 3 months before inclusion, and asymptomatic patient
4. History of primary immunodeficiency, history of organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy.
5. Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Intranasal/inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
6. Live attenuated vaccination administered within 30 days prior to randomization.
7. Known history of interstitial lung disease (asbestosis...) or CT-scan signs of interstitial lung disease.
8. Subjects with an active, known or suspected autoimmune disease, including systemic lupus erythematosis or Wegener's granulomatosis. Subjects with type I diabetes mellitis, or hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are permitted to enroll.
9. Active or history of inflammatory bowel disease (eg, diverticulitis, colitis, Crohn's), irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Note that diverticulosis is permitted.
10. Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to:

    * known prior history of active tuberculosis-disease;
    * known acute or chronic B or C hepatitis by serological evaluation. Patients with serological sequelae of hepatitis (antibodies test serologically positive for virus) without hepatitis could be included.
    * known Human immunodeficiency virus infection.
11. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
12. The last dose of prior chemotherapy or radiation therapy (with the exception of palliative radiotherapy) was received less than 3 weeks prior to randomization

Primary outcomes:
measure: Disease Control rate assessed by CT scan
timeFrame: 3-months
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 3-months
measure: Progression-Free Survival
timeFrame: 3-month
measure: Overall Survival
timeFrame: 3-months
measure: Quality of Life
timeFrame: 3-months
measure: prognosis impact of blood biomarkers (exploratory studies)
timeFrame: 3-months
Other outcomes:
Locations:
city: Angers
country: France
facility: Angers - CHU
city: Avignon
country: France
facility: Avignon - Institut Sainte-Catherine
city: Clermont-Ferrand
country: France
facility: CHU
city: Dijon
country: France
facility: Dijon - CHU
city: Grenoble
country: France
facility: Grenoble - CHU
city: Le Havre
country: France
facility: Centre Hospitalier - Pneumologie
city: Le Mans
country: France
facility: Centre Hospitalier - Pneumologie
city: Lille
country: France
facility: CHRU Lille - Hopital Calmette
city: Marseille
country: France
facility: AP-HM Hôpital Nord
city: Mulhouse
country: France
facility: Mulhouse - CH
city: Paris
country: France
facility: AP-HP Hopital Tenon - Pneumologie
city: Paris
country: France
facility: AP-HP Hôpital Bichat
city: Pierre Bénite
country: France
facility: HCL Lyon Sud
city: Pontoise
country: France
facility: Pontoise - CH
city: Rennes
country: France
facility: Rennes - CHU
city: Rouen
country: France
facility: Rouen - CHU
city: Saint-Nazaire
country: France
facility: Centre Etienne Dolet
city: Strasbourg
country: France
facility: CHU Strasbourg
city: Toulon
country: France
facility: Toulon - CHI
city: Toulouse
country: France
facility: Toulouse - CHU Larrey
city: Tours
country: France
facility: CHU Tours - Pneumologie
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Intergroupe Francophone de Cancerologie Thoracique
name: Arnaud Scherpereel, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Intergroupe Francophone de Cancerologie Thoracique
name: Gérard Zalcman, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16.